Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022

Abstract

Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of passive and active surveillance.

Keywords: Uganda; poliovirus; vaccine safety; vaccines; viruses.

Figure

Cohort event monitoring enrollment after novel oral poliovirus vaccine type 2 administration, Uganda, 2022. Ineligible children included those who were >59 months of age, demonstrated acute signs or symptoms at the time of vaccination, were without a caretaker who had access to a phone, did not reside in the community for >42 days after vaccination, were without a caretaker staying with the child for >42 days, or did not complete enrollment, as well as any other unspecified reason.